Drug Price Caps Are the Wrong Solution for Patients
By: Colorado BioScience Association Date: 07/29/2024
Patients say Upper Payment Limits (UPLs) won’t make their medicines more affordable. Colorado’s Prescription Drug Affordability Board (PDAB) hasn’t listened. Colorado’s PDAB was created to...
Learn MoreWeekly Policy Blog: FTC Blasts PBMs in New Report
By: Colorado BioScience Association Date: 07/16/2024
7/16/24 CBSA has consistently advocated for PBM reform at the state and federal level. Following the release of an interim report from the Federal Trade Commission (FTC) blasting the business pr...
Learn MoreWeekly Policy Blog: PDAB Moves Two More Drugs to Upper Payment Limit Rulemaking Process
By: Colorado BioScience Association Date: 07/08/2024
On July 3, the Colorado Prescription Drug Affordability Board (PDAB or Board) voted to initiate the upper payment limit (UPL) rulemaking process for two more drugs, Stelara and Cosentyx, after deeming...
Learn MoreWeekly Policy Blog: Urge Congress to Reauthorize the Rare Pediatric Disease Priority Review Voucher (PPRV) Program
By: Colorado BioScience Association Date: 06/25/2024
CBSA and BIO urge you to reach out to Senator Hickenlooper to encourage his support of S.4583, a bill that would reauthorize the rare pediatric disease priority review voucher (PPRV) program before it...
Learn MoreWeekly Policy Blog: CBSA Policy News Roundup—BIO International Convention and Prescription Drug Affordability Events
By: Colorado BioScience Association Date: 06/10/2024
This past week, the CBSA team represented our community and shared our expertise on prescription drug affordability at the BIO International Convention and through a series of virtual events: El...
Learn MoreWeekly Policy Blog: EPA, FDA, and USDA Release Joint Regulatory Plan for Biotechnology
By: Colorado BioScience Association Date: 05/28/2024
CBSA and our partners at Biotechnology Innovation Organization (BIO) welcome the joint plan that the U.S. Environmental Protection Agency (EPA), the U.S. Food and Drug Administration (FDA), and the U....
Learn MoreWeekly Policy Blog: LDT Final Rule Published
By: Colorado BioScience Association Date: 05/20/2024
The U.S. Food and Drug Administration (FDA) published a final rule overhauling its approach to the regulation of laboratory developed tests (LDTs) on May 6, 2024. The final rule, which is largely simi...
Learn MoreWeekly Policy Blog: Colorado’s 2024 Legislative Session Wraps Up
By: Colorado BioScience Association Date: 05/13/2024
Colorado’s 2024 legislative session, the Second Regular Session of the 74th General Assembly, concluded on May 8, the 120th day of session. During the final weeks of session, the Colorado BioScience A...
Learn MoreWeekly Policy Blog: HB24-1446 Supports Professional Development for Science Teachers
By: Colorado BioScience Association Date: 05/06/2024
HB24-1446, a bill that supports professional development for science teachers, has passed the General Assembly and will soon be sent to Governor Polis for his signature. The bill provides funding for...
Learn MoreWeekly Policy Blog: CBSA Advocates on Federal Issues During the BIO Fly-In
By: Colorado BioScience Association Date: 04/22/2024
Colorado Bioscience Association (CBSA) Vice President and Counsel for Policy + Advocacy, Amy Goodman, represented the Colorado life sciences ecosystem and advocated for community priorities on Capitol...
Learn More